The Australian MS Longitudinal Study (AMSLS) research platform is available for researchers, MS societies or other stakeholders who can benefit from this resource. The AMSLS study can provide de-identified data, collect new data, and assist with the recruitment for studies.
Scroll down for more information on data and survey requests and current AMSLS collaborative projects.
There are two main types of data:
An overview of the AMSLS dataset is provided below.
The AMSLS can include a number of questions to AMSLS surveys, or can run standalone surveys for you.
The AMSLS is willing to assist with the recruitment of participants for studies with ethics approval. The AMSLS should be reimbursed for any costs associated with the recruitment.
For a list or to request copies of past surveys please contact AMSLS.firstname.lastname@example.org.
Monash University, Department of Management – The AMSLS study has a focus on employment issues. This work is done in collaboration with Associate Professor Pieter van Dijk and Associate Professor Andrea Kirk Brown from Monash University. Maintaining employment for people with MS is made difficult due to the impact of disease related symptoms on their ability to perform their job. Symptoms alone, however, do not explain the high rates of turnover for employees with MS. We track employment rate in people with MS compared to the Australian population. In addition, we examine the extent to which employees with MS perceive they feel trusted and respected in the workplace, and safe to participate fully at work, and the consequent impact of these perceptions on their decision to (a) voluntarily disclose their diagnosis, and (b) their intentions to remain in employment.
The Menzies MS Research Group has been funded (MS Research Australia, $180,000, 2016-2017) to compare MS patients from Australia and New Zealand. Australian MS patients with Relapsing-Remitting MS have been largely treated while the treatment rules in New Zealand have been far more restrictive. This study will answer the question whether the use of very costly disease-modifying therapies in MS has had a significant positive impact on the long-term clinical course.